New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk

New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in some patients at low fracture risk.

This is a case of labeling catching up with the evidence.

Bisphosphonates persist in the bones for years. So 3 to 5 years is enough for many patients...because benefits seem to last even after treatment is stopped.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote